This study explo res the possible use of reactive oxygen-activated DNA modifying agent s against acute myeloid leukemia (AML). A key amine on the lead agent was investigated via cytotoxicity assays and was found necessary for potency. The two best compounds were screened via the NCI-60 cell panel. These two compounds had potency between 200 and 800 nM against many of the leukemia cancer cell types. Subsequent experiments explored activity against a transformed AML model that mimics the molecular signatures identified in primary AML patient samples. A lead compound had an IC 50 of 760 nM against this AML cell line as well as a therapeutic index of 7.7 ± 3 between the transformed AML model cell line and non-cancerous human CD34+ blood stem/progeni tor cells (UCB). The selectivity was much greater than the mainstays of AML treatment: doxorubicin and cytarabine. This manuscript demonstrates that this nov el type of agent may be useful against AML.
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Anticancer agents that exert their mechanis m of action through DNA modification form a backbone of many anticancer therapies. Leukemia is often treated with nucleoside analogs and/or DNA intercalatin g agents. 1, 2 For example, acute myeloid leukemia (AML) is treated with combination chemotherapy involving cytarabine, a nucleoside analog, and doxorubicin, a DNA intercalator . 1 Among the various types of leukemia, AML has the poorest prognosis, with a 5-year survival rate of 5-60% depending on prognostic factors. 3 Thus, there is a need for new, efficacious therapeutic agents with high selectivity for AML. Previous ly, we described novel agents that are activated by reactive oxygen species (ROS) to become DNA-modify ing agents. 4, 5 Given the use of DNA-modifyin g agents in leukemia, we sought to determine if these novel agents could be useful against a leukemia with high levels of ROS. 6 Elevated levels of ROS are thought to play a vital role in AML. Excess ROS benefits malignant cells by upregulating redox-regulated growth and survival factors. [7] [8] [9] Importan tly, examples of genetic changes that confer an elevated ROS phenotype are plentiful within AML. The internal tandem duplication of the FLT3 gene, a common AML genotype, leads to increased ROS. 10, 11 In addition, permanent activation of RAS oncogenes causes the overexpression of proteins that promote cancer cell proliferation as well as lower the concentratio n of cellular antioxidant enzymes, thereby increasing ROS. [12] [13] [14] Because of the strong relationshi p between ROS and AML, we hypothesize d that ROS-activat ed agents would be useful as treatment against AML. In this manuscript we utilize a recently developed cellular model of AML whereby we express the leukemia-as sociated oncogene MLL-AF9 in human blood stem/progen itor cells and use these cells in vitro and in animal models to study the mechanism s associated with transformat ion. 15 The molecular signatures associated with these AML cells closely mimic those identified in primary AML patient samples. 15 Thus, potency experime nts between these novel models and blood stem cells accurately reflect relative specificity of our ROS-activat ed DNA modifying agents.
Chemists have begun to recognize elevated ROS in cancer cells as a therapeutic design strategy. 16, 17 We should note that ROS-associated agents have been used for many years, as both arsenic trioxide and doxorubici n generate ROS as part of their mechanis ms of action. [18] [19] [20] Initial strategies to utilize elevated ROS in cancer cells focused on the inactivation of glutathione . 21 Newer ROS-associated approach es use pro-drugs that possess a hydrogen peroxide sensitive boronic ester or agents that release toxic metabolites . [22] [23] [24] In the approach described here, the agents were designed to have a unique activation mechanism, which requires ROS (Fig. 1) . These agents induce a large and bulky phenol lesion which requires DNA repair for cellular survival as part of their mechanis m of action. 5 Here, we describe the evaluation of several ROS-activat ed DNAmodifyin g agents. The agents were initially screened against HeLa cells, which revealed the importance of a tethered aniline. Next, we investigated the potency of two lead compound s against a panel of 60 cell lines through the National Cancer Institute as well as on human AML cells. We found that one of the ROS-activated DNA-modifying agents had an IC 50 of 760 nM against AML cells compared with an eightfold lower potency against normal CD34+ blood stem/progen itor cells. The selectivity of this agent was greater than the DNA alkylatin g agents cisplatin and chloramb ucil as well as doxorubicin and cytarabine (ara-C), two agents which are mainstays of AML treatment.
We previously published the structures of two novel ROS-activated DNA-mo difying agents, compounds 3 and 5.
4,5 We systematically modified the agents in order to assess the role of the amine ( Table 1) . Synthesis of an aniline derivative which lacked an N-alkyl group, compound 1, was accomplished . Compared to previously published 3, in which the amine was an N-ethylanilin e, 1 had a modest reduction in cytotoxicity, down to 30 ± 6 lM from 23 ± 5 lM. Potency was restored to 18 ± 3 lM when the agent possessed an N-methylaniline , as seen in compound 2. Replacemen t of the methyl with a much more bulky, isopropyl group at the aniline nitrogen, as in 4, resulted in a threefold decrease in potency relative to compound 2. The IC 50 of 4 was 53 ± 7 lM. When a second, reactive hydroquino ne moiety was added to the other alkyl position, as in 5, potency doubled relative to compound 3. We further investigated the effect of the carbon chain between the amine and the hydroquino ne ether, based on both 2 and 3. In 6, a compound containing an N-ethylanil ine and a three-carbon chain, the IC 50 value was 14 ± 3 lM. The N-methylaniline with a three-carbon chain, 7, led to a change in IC 50 to 9 ± 2 lM. Both 6 and 7 indicated that increasing the carbon chain length was favorable. The chain was further lengthened to four carbons for 8 and five carbons for 9, and IC 50 values changed to 12 ± 3 and 13 ± 2 lM, respectively .
Our results indicated a linker of three to five carbons yielded potent compound s. When we investigated the aniline ring system, we found that conversio n to a benzylamin e, 10, decreased potency to 33 ± 3 lM from 18 ± 3 lM. Furthermore, when the aniline amine was changed to an amide, as in compound 11, anticancer cell activity was eliminated. When the aniline was complete ly removed, 12, we found no potency, indicating that the presence of the amine is required. Therefore, potency was strongly altered by direct inactivation of the amine. Additional negative controls were synthesized. In compound 13, exchanging the hydroquinone ether to a phenol ether led to the complete loss of potency. Compound 13 is not oxidizeable, which infers that anticancer activity requires oxidation. Finally, compound 14, which lacked a hydroquino ne moiety entirely, demonstrated loss of potency. Compound 14 is a traditional type of DNA alkylating agent, which infers that ROS-activat ed agents utilize a new and innovative mechanis m of action, which requires an amine for potency.
IC 50 values, in lM, are the mean of six replicates from two independent experime nts. All values normalized to 3.
In our previous work, a limited number of cell lines were assessed via MTT cell viability assay. 4 The relationship was complex with some cell lines being affected much more than others. We, therefore, decided to assess compound toxicity on a larger panel of cells. Compounds 5 and 7 were evaluated for effects on the viability of the cell lines in the NCI-60 cell panel ( Table 2) . The NCI panel screen has a few changes compared to an MTT assay. First, viability is monitored using a Sulforhodam ine B assay. The Sulforhod amine B assay is used to measure s total protein content, and therefore, is a measure of cell number rather than metabolic activity. 25 We found little differenc e in the measured values via the two methods. The second difference is that the data is reported as GI 50 rather than IC 50 to reflect the change in cell counts relative to the starting number of cells. Compound s 5 and 7 showed selective potency against particular cell lines in the sixty-cell panel. The median GI 50 for 5 was 3.9 lM and 3.0 lM for 7 (Table 2) . Importantly, the distribution of GI 50 values was large, with a range of 55-fold for 5 and 53-fold for 7. This Figure 1 . The general structure of the molecules synthesized and examined. In the presence of ROS, a potent electrophile is generated. These compounds transfer a phenol (grey) to DNA to form a cytotoxic hydroxy-N2,3-benzetheno-2 0 -deoxyguanosine adduct. We then focused on AML since it is the leukemia with the poorest prognosis. To fully assess the anticance r activity against AML, we were intereste d in comparing transformed cells to closely related, yet non-trans formed counterparts. In the case of AML, the generally accepted non-transform ed cell of origin is the human CD34+ blood stem/progen itor cell. 26 Assessing potency against normal blood stem cells is important since, without proper selectivity, a cytotoxic agent will yield reduced efficacy and therapeutic potential. One major limitation to current treatment is that many anticance r agents do not selective ly inhibit growth or cause cytotoxicity to cancer cells relative to healthy cells. Therefore, a comparison of current agents and our ROS-activated chemothera peutics was necessar y. Accordingly , we measured cytotoxicity of our compounds on CD34+ blood stem/progenito r cells and on the MA9.3 AML cell line, which was derived from the transformat ion of human CD34+ cells by introduct ion of the leukemia oncogene MLL-AF9 . 15 Therapeutic indices for ROS-activated DNA-modifyin g agents and known anticancer agents were determined (Fig. 2) . The foundations of AML treatment are the anticancer agents doxorubicin and ara-C. Doxorub icin and ara-C showed strong potency against MA9.3 AML cells with IC 50 values of 86 ± 5 nM and 0.92 ± 0.03 lM respectively; these agents had IC 50 values against CD34+ blood stem/progenitor cells of 76 ± 18 nM and 0.59 ± 0.09 lM. These agents had very limited selectivity. The therapeutic index for doxorubicin was 0.9 ± 0.2 and the index for ara-C was 0.6 ± 0.1. The negative index for ara-C was statistically significant but small. Thus, these two agents showed low selectivity. We then determined if other commercially available DNA-modifyin g agents were selective , as a base of comparison for our ROS-activat ed DNA-mo difying agents. We chose cisplatin for its high therapeuti c use and chlorambuci l for its utilization in chronic lymphocytic leukemia. The IC 50 value for cisplatin was 14 ± 0.7 lM and for chloramb ucil was 8.7 ± 0.3 lM against MA9.3 AML cells. Against CD34+ blood stem/progen itor cells, the former had an IC 50 value of 15 ± 2 lM, while the latter had an IC 50 value of 11 ± 1 lM. The therapeutic index for cisplatin was 1.0 ± 0.2, while the index for chlorambucil was 1.3 ± 0.1. Chlorambucil did, therefore, show some selectivity , although slight. Our ROS-activat ed DNA-modify ing agents were investigated; Compound 5 had an IC 50 value of 3.0 ± 0.2 lM and 7 had an IC 50 value of 0.7 ± 0.2 lM against MA9.3 cells. The IC 50 values against normal blood stem cells were 16 ± 1 lM and 5.4 ± 0.9 lM for 5 and 7, correspondingl y. The therapeuti c indices were 5.3 ± 0.5 and 7.7 ± 3 for 5 and 7, respectivel y. Conseque ntly, ROS-activated DNA-modifyin g agents have favorable therapeutic indices and statistically significant selectivity against AML cancer cells.
The systematic syntheses in this manuscript have helped to uncover important factors for potency of our ROS-activated DNAmodifying agents. We have found that a tethered amine is required. First, extreme changes like removal of the nucleophile , conversion to an amide, or steric blocking severely reduced potency. This manuscr ipt identified a new lead compound, 7, which has many favorable anticancer agent propertie s such as a high therapeutic index and potency in the nM range against several leukemia cell lines.
The ROS-activat ed DNA-modify ing agents we investiga ted were selective for AML over normal CD34+ blood stem/progen itor cells. We should note than when testing these agents on normal blood CD34+ cells, we found that 5 and 7 had a potency of 16 ± 1 lM and 5.4 ± 0.9 lM, respectively. Thus, many cancer cell lines were selectively targeted to some extent. The most potent compound, 7, had a therapeuti c index of 7.7 ± 3 for the MA9.3 AML cell line. The NCI panel allows for analysis by COMPARE, which is an algorithm to correlate the cytotoxic profile with that of other agents. 27 Interestingl y, no significant correlation to known anti-cancer agents is observed for both 5 and 7. Therefore, ROS-activated DNA-modify ing agents are a novel class of chemothera peutics with distinct cellular mechanisms. In addition, this manuscript highlights AML with its poor prognosis, are natural targets for ROS-activat ed DNA-modifyin g agents as well as for the several other medicinal chemistry teams that are pursuing ROS-based agents. [16] [17] [18] [19] [20] [21] [22] [23] 
